File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/j.oraloncology.2017.02.002
- Scopus: eid_2-s2.0-85012235753
- PMID: 28351581
- WOS: WOS:000397953800009
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Characterization of PD-L1 expression and immune cell infiltration in nasopharyngeal cancer
Title | Characterization of PD-L1 expression and immune cell infiltration in nasopharyngeal cancer |
---|---|
Authors | |
Keywords | Prognosis Tumour-infiltrating lymphocytes Programmed cell death-ligand 1 (PD-L1) Overall survival Nasopharyngeal carcinoma Disease-free survival CD8-positive T-lymphocytes |
Issue Date | 2017 |
Citation | Oral Oncology, 2017, v. 67, p. 52-60 How to Cite? |
Abstract | © 2017 Elsevier Ltd Objectives Locally recurrent or metastatic nasopharyngeal cancer (NPC) remains an important challenge, with more effective and durable therapeutic options needed. Cancer immunotherapy, and in particular therapies that target the PD-L1/PD-1 immune checkpoint pathway, may provide new options to treat NPC patients. This study evaluated PD-L1 and CD8 expression levels and the respective associations with clinical and histopathological characteristics of patients with NPC. Materials and methods Diagnostic tumour biopsies were obtained before radical radiotherapy with or without chemotherapy from 161 patients with NPC. These biopsies were analysed for PD-L1 expression levels on tumour cells (TC) and tumour-infiltrating immune cells (IC), and for CD8 T-cell infiltration. Results were correlated with baseline characteristics and clinical outcomes with standard-of-care treatment regimens. Additionally, pre- and post-treatment–paired tumour samples were analysed (n = 146). Results 75% of tumours expressed PD-L1 on IC and 24% on TC. Baseline clinical characteristics of stage, sex and age did not correlate with PD-L1 expression. Additionally, overall survival and progression-free survival of standard-of-care treatment did not correlate with baseline PD-L1 expression. CD8 levels did correlate with clinical outcomes; however, results were confounded by other baseline characteristics. After treatment, PD-L1 expression dropped a median of 1.5% on IC and a median of 2.75% on TC. Median CD8 expression dropped 1.9%. Conclusions Majority of NPC biopsy samples demonstrated PD-L1 expression on ⩾1% of IC, with fewer expressing PD-L1 on TC. In contrast to previous smaller studies, no prognostic value was observed for PD-L1 expression levels in patients with NPC. |
Persistent Identifier | http://hdl.handle.net/10722/282110 |
ISSN | 2023 Impact Factor: 4.0 2023 SCImago Journal Rankings: 1.257 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chan, Oscar Siu Hong | - |
dc.contributor.author | Kowanetz, Marcin | - |
dc.contributor.author | Ng, Wai Tong | - |
dc.contributor.author | Koeppen, Hartmut | - |
dc.contributor.author | Chan, Lai Kwan | - |
dc.contributor.author | Yeung, Rebecca Mei Wan | - |
dc.contributor.author | Wu, Haiyan | - |
dc.contributor.author | Amler, Lukas | - |
dc.contributor.author | Mancao, Christoph | - |
dc.date.accessioned | 2020-04-29T07:36:05Z | - |
dc.date.available | 2020-04-29T07:36:05Z | - |
dc.date.issued | 2017 | - |
dc.identifier.citation | Oral Oncology, 2017, v. 67, p. 52-60 | - |
dc.identifier.issn | 1368-8375 | - |
dc.identifier.uri | http://hdl.handle.net/10722/282110 | - |
dc.description.abstract | © 2017 Elsevier Ltd Objectives Locally recurrent or metastatic nasopharyngeal cancer (NPC) remains an important challenge, with more effective and durable therapeutic options needed. Cancer immunotherapy, and in particular therapies that target the PD-L1/PD-1 immune checkpoint pathway, may provide new options to treat NPC patients. This study evaluated PD-L1 and CD8 expression levels and the respective associations with clinical and histopathological characteristics of patients with NPC. Materials and methods Diagnostic tumour biopsies were obtained before radical radiotherapy with or without chemotherapy from 161 patients with NPC. These biopsies were analysed for PD-L1 expression levels on tumour cells (TC) and tumour-infiltrating immune cells (IC), and for CD8 T-cell infiltration. Results were correlated with baseline characteristics and clinical outcomes with standard-of-care treatment regimens. Additionally, pre- and post-treatment–paired tumour samples were analysed (n = 146). Results 75% of tumours expressed PD-L1 on IC and 24% on TC. Baseline clinical characteristics of stage, sex and age did not correlate with PD-L1 expression. Additionally, overall survival and progression-free survival of standard-of-care treatment did not correlate with baseline PD-L1 expression. CD8 levels did correlate with clinical outcomes; however, results were confounded by other baseline characteristics. After treatment, PD-L1 expression dropped a median of 1.5% on IC and a median of 2.75% on TC. Median CD8 expression dropped 1.9%. Conclusions Majority of NPC biopsy samples demonstrated PD-L1 expression on ⩾1% of IC, with fewer expressing PD-L1 on TC. In contrast to previous smaller studies, no prognostic value was observed for PD-L1 expression levels in patients with NPC. | - |
dc.language | eng | - |
dc.relation.ispartof | Oral Oncology | - |
dc.subject | Prognosis | - |
dc.subject | Tumour-infiltrating lymphocytes | - |
dc.subject | Programmed cell death-ligand 1 (PD-L1) | - |
dc.subject | Overall survival | - |
dc.subject | Nasopharyngeal carcinoma | - |
dc.subject | Disease-free survival | - |
dc.subject | CD8-positive T-lymphocytes | - |
dc.title | Characterization of PD-L1 expression and immune cell infiltration in nasopharyngeal cancer | - |
dc.type | Article | - |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1016/j.oraloncology.2017.02.002 | - |
dc.identifier.pmid | 28351581 | - |
dc.identifier.scopus | eid_2-s2.0-85012235753 | - |
dc.identifier.volume | 67 | - |
dc.identifier.spage | 52 | - |
dc.identifier.epage | 60 | - |
dc.identifier.eissn | 1879-0593 | - |
dc.identifier.isi | WOS:000397953800009 | - |
dc.identifier.issnl | 1368-8375 | - |